RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Patents have value Yes and I think that's the point that Canopy will be trying to make - that these procedural patents already exist in Pharma and it is no different.
The argument on the other side (GW) may be that a) these procedures were widely used (albeit In mostly illegal operations) far before it was patented, and b) that the slight changes in procedures that GW has implemented compared to Canopy make it a completely different procedure.
As a NL investor, I am really hoping for a Canopy judgement here. Not only will it make NL's patents stronger, but it will shine a big light on the importance of IP in the cannabis industry. And validate NL's business strategy since 2017.
I wonder how long it will take to get a result in this case.